Is energy based physiotherapy use reasonable for those who do not have female sexual dysfunction?

HIFEM technology – innovative physiotherapeutic method for diminishing weakness of pelvic floor muscles (PFM). Its effect is based on intense focused electromagnetic fields, causing contractions of higher tension than Maximal Voluntary contractions of PFM. As strong PFM is associated with high sexual function and satisfaction, HIFEMt is believed to have great prospectivesin treatment of Female Sexual dysfunction (FSD). But could it be used to improve sexual life in case of normal sexual function? 40 women, aged 25 to 45, selected according to specific criteria, underwent ten HIFEM technology procedures according to local regimen. Data was obtained from questionnaires, filled before the 1stand the 10thprocedures, using validated FSFI – suggesting FSFI<26.55 for the diagnosis of FSD – and supplementary questions. Data was processed with Microsoft Excel and IBM SPSS Statistics 22.0. 60%(n=21) of patients were nullipara.50%(n=7) of those, who had ≥1childhad episiotomy/ruptures during labor.  48.6%(n=17) named anorgasmia as the reason of participation in the research, 42%(n=15) – libido problems, 20% (n=7) – pain during intercourse. Before the start of procedure cycles 60%(n=24) of all patients had FSD, with the mean(IQR)value 22.50(4.85) with the lowest numbers in Desire domain (3.10(1.00)). 87.5%(n=35) of patients have underwent full procedure cycle. 12.5%(n=5) were excluded because of developing contraindications for the procedures(pregnancy, acute infections, hemorrhoid disease). 5.7%(n=2) developed complications after 7thand 10thprocedure(PFM hypertonus (n=2)), both non-FSD group. After the 10thprocedure 42.9% had FSD(n=15) with FSFI 27.17(3.58). The biggest changes were in Orgasm domain (0.84(1.37)) after the 5th; 0.93(1.6) after the 10th.Medians(Q1-Q3) of FSFI changes from 1sttill 10thprocedure between FSD group and non-FSD group were statistically significant: 6.1(3.1-11.1) and 1.9(-3.1-5.0). HIFEMt shows better results in symptomatic therapy of FSD than as method of improvement of previously normal sexual function – its use for non-FSD patients is possible, however each case should be considered individually. Further evaluation needed.